Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates

Parabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate at the 32-week landmark and a favorable safety and tolerability profile

Event · Earnings
Original reporting
Published Nov 12, 2026, 12:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PBLS
Bullish
high confidence
Mentioned
$PBLS
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PBLSBullishMed
01

Why it matters

The disclosed ORR and FDA alignment are new, material facts that can move the stock.

02

Market read

First‑report of strong Phase 1/2 data and a $1.1 B cash position, likely to attract biotech investors.

03

What to watch

Potential dilution from future financing rounds if trial timelines extend beyond 2029.

Relevance 8/10Novelty 9/10Timing: after‑hours filing
AlphAI · Earnings readPBLS · Q3 2026 · ended 2026-09-30

Parabilis reports Q3 2026 net loss of $44.5 million and $1.1 billion in cash, with Phase 3 PEDESTAL planning aligned with the FDA

→Mixed quarter

The filing shows clinical progress, FDA alignment on the PEDESTAL Phase 3 design, and a cash position of $1.1 billion that the company says funds operations into 2030. Against that, quarterly revenue is only $2.1 million, operating costs rose on higher R&D and G&A, and the net loss widened to $44.5 million from $33.5 million a year earlier. The release does not include any financial outlook.

Revenue
$2.11M
EPS · GAAP
$(0.36)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue (three months ended Sep 30, 2026)GAAP$2.11M––
Collaboration revenue (three months ended Sep 30, 2026)GAAP$671K––
Collaboration revenue, related party (three months ended Sep 30, 2026)GAAP$1.44M––
Research and development expenses (three months ended Sep 30, 2026)GAAP$45.60M–$17.4 million increase
General and administrative expenses (three months ended Sep 30, 2026)GAAP$11.25M–$4.7 million increase
Total operating expenses (three months ended Sep 30, 2026)GAAP$56.85M––
Loss from operations (three months ended Sep 30, 2026)GAAP−$54.74M––
Interest income (three months ended Sep 30, 2026)GAAP$10.37M––
Interest expense (three months ended Sep 30, 2026)GAAP−$124K––
Sublease income, related party (three months ended Sep 30, 2026)GAAPnot reported in the quarter (printed as a dash)––
Total other income, net (three months ended Sep 30, 2026)GAAP$10.24M––
Net loss (three months ended Sep 30, 2026)GAAP−$44.49M–$11.0 million increase in net loss
Net loss allocable to common stockholders (three months ended Sep 30, 2026)GAAP−$44.49M––
Net loss per share, basic and diluted (three months ended Sep 30, 2026)GAAP$(0.36)––
Comprehensive loss (three months ended Sep 30, 2026)GAAP−$46.39M––
Total revenue (nine months ended Sep 30, 2026)GAAP$2.26M––
Collaboration revenue (nine months ended Sep 30, 2026)GAAP$819K––
Collaboration revenue, related party (nine months ended Sep 30, 2026)GAAP$1.44M––
Research and development expenses (nine months ended Sep 30, 2026)GAAP$122.7M––
General and administrative expenses (nine months ended Sep 30, 2026)GAAP$32.61M––
Total operating expenses (nine months ended Sep 30, 2026)GAAP$155.3M––
Loss from operations (nine months ended Sep 30, 2026)GAAP−$153.1M––
Interest income (nine months ended Sep 30, 2026)GAAP$16.99M––
Interest expense (nine months ended Sep 30, 2026)GAAP−$626K––
Sublease income, related party (nine months ended Sep 30, 2026)GAAPnot reported in the period (printed as a dash)––
Change in fair value of simple agreement for future equity (nine months ended Sep 30, 2026)GAAP−$5.56M––
Total other income, net (nine months ended Sep 30, 2026)GAAP$10.80M––
Net loss (nine months ended Sep 30, 2026)GAAP−$142.3M––
Net loss allocable to common stockholders (nine months ended Sep 30, 2026)GAAP−$182.3M––
Net loss per share, basic and diluted (nine months ended Sep 30, 2026)GAAP$(3.51)––
Cash, cash equivalents and marketable securities (as of Sep 30, 2026)GAAP$1.1B––

Capital returns

  • The filing does not report any share repurchase or common stock dividend for the period.

What drove it

  • The company states that the increase in R&D expenses of $17.4 million was primarily driven by ongoing investment in the clinical development of zolucatetide across a number of indications and by increased employee-related costs, including stock-based compensation, tied to increased hiring.
  • The company states that the increase in G&A expenses of $4.7 million was primarily attributable to higher employee-related costs, including stock-based compensation, related to increased hiring, and to expenses associated with operating as a public company.
  • The company states that the increase in net loss of $11.0 million was primarily driven by increased operating costs.
  • Interest income rose to $10,369 thousand in the quarter from $711 thousand a year earlier. The release does not state the reason for the change.
  • Clinical milestones reported in the release: ESMO 2026 presentation with ORR of 72.2% (13/18) at the 32-week landmark for patients with a starting dose of 450 mg or more; DCR of 100% across 46 response-evaluable patients at that dose; FDA alignment on the PEDESTAL Phase 3 design, with a first-half 2027 start and topline results anticipated in 2029; new FAP dose-ranging cohort; and a clinical collaboration with Revolution Medicines in RAS G12D mutant MSS CRC.

Concerns

  • Net loss for the quarter was $(44,491) thousand, up from $(33,475) thousand a year earlier, and for the nine months it was $(142,270) thousand, up from $(106,611) thousand.
  • Total operating expenses for the quarter were $56,850 thousand against $34,845 thousand a year earlier, and the loss from operations was $(54,736) thousand.
  • Quarterly revenue of $2,114 thousand is small relative to operating expenses. Collaboration revenue is shown as $671 thousand plus $1,443 thousand from a related party.
  • Net loss per share was $(0.36) for the quarter, compared with $(21.66) a year earlier. The prior-year figure reflects a much smaller share count, and the release also shows a weighted average share count of 123,593,149 against 2,025,284 a year earlier.
  • Interest income of $10,369 thousand is a material part of the quarter's other income. The release does not describe how interest income will develop.
  • The release states that the PEDESTAL Phase 3 trial is planned to start in the first half of 2027, with topline results anticipated in 2029.

What to watch

  • Start of the PEDESTAL Phase 3 registrational trial in desmoid tumors, planned for the first half of 2027.
  • Translational data on on-target activity in FAP and additional FAP clinical data, both anticipated in the first quarter of 2027.
  • Updated clinical data in adamantinomatous craniopharyngioma, anticipated in the first half of 2027.
  • HCC clinical data, anticipated at a medical meeting in the first quarter of 2027.
  • Oral presentation at the CTOS Annual Meeting in November 2026, featuring the June 22, 2026 data cut.
  • Operating expense trajectory: R&D and G&A increases are attributed by the company to clinical development and hiring.
  • Progress of the Revolution Medicines collaboration in RAS G12D mutant MSS CRC, where Parabilis will sponsor and conduct the study and RevMed will share trial costs equally.
  • Investor conferences: Jefferies Global Healthcare Conference on November 16, 2026, and Evercore ISI 9th Annual Healthcare Conference on November 30, 2026.

Balance sheet and cash flow

  • Cash and cash equivalents as of Sep 30, 2026: $521,198 thousand (Dec 31, 2025: $27,711 thousand).
  • Marketable securities, current as of Sep 30, 2026: $350,425 thousand (Dec 31, 2025: no amount printed).
  • Marketable securities, non-current as of Sep 30, 2026: $201,309 thousand (Dec 31, 2025: no amount printed).
  • Total assets as of Sep 30, 2026: $1,131,242 thousand (Dec 31, 2025: $80,820 thousand).
  • Total liabilities as of Sep 30, 2026: $126,895 thousand (Dec 31, 2025: $97,344 thousand).
  • Deferred revenue, current portion as of Sep 30, 2026: $13,544 thousand; deferred revenue, net of current portion: $27,304 thousand.
  • Term loan, net of discount, current as of Sep 30, 2026: $2,000 thousand (Dec 31, 2025: $13,077 thousand).
  • Total stockholders' equity as of Sep 30, 2026: $1,004,347 thousand (Dec 31, 2025: deficit of $(526,495) thousand).
  • Convertible preferred stock: no amount as of Sep 30, 2026 (Dec 31, 2025: $509,971 thousand).
  • The company states that its cash, cash equivalents and marketable securities are expected to fund operations into 2030.
  • The filing does not include a cash flow statement.

Analysis

Parabilis reported a third quarter 2026 with total revenue of $2,114 thousand, all from collaboration agreements, against no revenue in the comparable prior-year quarter. Operating expenses rose to $56,850 thousand from $34,845 thousand, with R&D at $45,597 thousand (up from $28,199 thousand) and G&A at $11,253 thousand (up from $6,646 thousand). The loss from operations was $(54,736) thousand, and the net loss was $(44,491) thousand against $(33,475) thousand a year earlier. The company attributes the R&D increase to clinical development of zolucatetide across several indications and related hiring, and the G&A increase to employee-related costs, public company expenses and hiring. Net loss per share was $(0.36) for the quarter, and $(3.51) for the nine months, on a share count that changed substantially during the year, as the release shows a weighted average count of 123,593,149 for the quarter against 2,025,284 a year earlier.

The nine-month figures show the same pattern. Operating expenses were $155,337 thousand against $111,606 thousand, and the net loss was $(142,270) thousand against $(106,611) thousand. Other income partly offset operating costs: interest income was $16,987 thousand for the nine months against $3,017 thousand, and total other income, net was $10,805 thousand against $4,995 thousand. Sublease income from a related party was not reported in 2026, against $3,171 thousand in the prior-year nine months, and a $(5,556) thousand change in the fair value of a simple agreement for future equity appears in 2026 only. The release does not explain these items beyond the figures.

On the balance sheet, cash, cash equivalents and marketable securities were $1.1 billion at September 30, 2026. Cash and cash equivalents were $521,198 thousand, current marketable securities $350,425 thousand and non-current marketable securities $201,309 thousand, compared with $27,711 thousand of cash and cash equivalents at December 31, 2025. Total assets rose to $1,131,242 thousand from $80,820 thousand, and total stockholders' equity was $1,004,347 thousand, against a deficit of $(526,495) thousand at year-end 2025. The company states that this cash is expected to fund operations into 2030. Convertible preferred stock of $509,971 thousand at December 31, 2025 no longer appears on the September 30, 2026 balance sheet. Deferred revenue totals $13,544 thousand current and $27,304 thousand non-current, and the term loan, net of discount, is $2,000 thousand as current debt. The filing contains no cash flow statement, so operating and free cash flow cannot be read from it.

The clinical update is the main content of the release. The company reports an objective response rate of 72.2% (13/18) at the 32-week landmark among evaluable patients with a starting dose of 450 mg or more, a disease control rate of 100% across 46 response-evaluable patients at that dose, and no discontinuations due to treatment-related adverse events in 76 patients. It reports FDA alignment on a global Phase 3 design for PEDESTAL, with an initiation planned for the first half of 2027 and topline results anticipated in 2029. The release does not give any financial guidance, and no prior outlook was supplied, so no comparison against guidance is possible. The read on this quarter therefore rests on the reported results: clinical and regulatory milestones and a $1.1 billion cash position against a widening loss and rising operating costs that the company ties to its development and hiring plans.

Management, verbatim

With our Phase 3 dosing, regimen and trial design aligned with the FDA, we are well positioned to initiate PEDESTAL in the first half of 2027, bringing us closer to delivering a potentially transformative treatment for patients with desmoid tumors.

Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President

The updated results presented at ESMO further reinforce our confidence in the depth and consistency of desmoid tumor responses, alongside a favorable safety and tolerability profile.

Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President

Not in the filing

stated, not guessed
  • No financial guidance for revenue, operating expenses or other metrics is provided in the release, and no prior outlook was supplied.
  • Prior-quarter (June 30, 2026) figures are not printed, so sequential changes cannot be stated.
  • Year-over-year percentage changes are not printed for most lines; only the dollar increases for R&D ($17.4 million), G&A ($4.7 million) and net loss ($11.0 million) are given in the text.
  • No segment reporting is provided; revenue is shown only by revenue line (collaboration revenue and collaboration revenue from a related party).
  • No cash flow statement is provided, so operating cash flow, investing cash flow and free cash flow are not available.
  • Cash, cash equivalents and marketable securities of $1.1 billion has no printed prior-year or prior-quarter comparison on the same basis; the Dec 31, 2025 comparison of $27.7 million in the text matches cash and cash equivalents only.
  • No non-GAAP measures are reported.
  • No share price, consensus estimates or analyst expectations are included in the filing.
  • The release does not state the reason for the change in interest income, the change in fair value of the simple agreement for future equity, or the absence of sublease income in 2026.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

The filing combines financial results with clinical updates for Parabilis Medicines, a Nasdaq‑listed biotech focused on undruggable targets.

Company-level read

Ticker impact

$PBLSBullishHigh confidence
Context

Parabilis Medicines filed an 8‑K reporting Q3 2026 results and disclosed Phase 1/2 data showing a 72.2% objective response rate in desmoid tumor patients.

Expected impact

likely upside as investors price in the high response rate and extended runway

Evidence & confidence

First disclosure of robust Phase 1/2 efficacy, alignment with FDA for Phase 3, and $1.1 B cash balance provide material upside catalysts.

Market effects

strengthens the Wnt‑targeted oncology niche and may boost peer biotech valuations

limited to US biotech investors

modest, confined to specialty pharma sector

Counterpoint

If the Phase 3 design faces regulatory delays, the cash runway may not translate into near‑term price gains.

Key entities

  • Parabilis Medicines, Inc.

    Clinical‑stage biopharma developing zolucatetide

  • Revolution Medicines

    Partner in MSS colorectal cancer combination study

Every PBLS earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$PBLSMedAI 8/10

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Parabilis reported a 72% response rate for its drug, comparing it to published data of 41% for nirogacestat and 55.7% for varegacestat. The company plans a Phase III trial for 2027, with a regimen of 450 mg weekly followed by 300 mg every two weeks. Parabilis has aligned with the FDA on the trial design, aiming for a broad patient population and progression-free survival as the primary endpoint.

$PBLSMedAI 9/10

Parabilis reports phase 1/2 data for desmoid tumor treatment

Parabilis Medicines (PBLS) reported phase 1/2 trial results for zolucatetide, showing a 72.2% response rate in 18 patients and 100% disease control in 46 patients. The company plans to start a phase 3 trial in 2027, with FDA alignment on study design and endpoints. Zolucatetide has Fast Track and Orphan Drug Designations for desmoid tumors.